Amino acids as promoieties in prodrug design and development

Advanced Drug Delivery Reviews

Volumn 65, Issue 10, 2013, Pages 1370-1385

  Vig, Balvinder S ^a   Huttunen, Kristiina M ^b   Laine, Krista ^b   Rautio, Jarkko ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Challenges; Drug delivery; Formulation; Hydrolysis; Permeability; Solubility; Stability; Targeting; Transporters

Indexed keywords

CHALLENGES; DESIGN AND DEVELOPMENT; FORMULATION; PHYSICOCHEMICAL PROPERTY; PRECLINICAL DEVELOPMENT; STRUCTURAL DIVERSITY; TARGETING; TRANSPORTERS;

CONVERGENCE OF NUMERICAL METHODS; DRUG DELIVERY; DRUG PRODUCTS; HYDROLYSIS; MECHANICAL PERMEABILITY; SOLUBILITY;

AMINO ACIDS;

5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; ACICLOVIR; AMINO ACID DERIVATIVE; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIOXIDANT; ARBACLOFEN PLACARBIL; BRIVANIB ALANINATE; CAM 4451; CAM 4562; EGLUMETAD; GABAPENTIN ENACARBIL; GANCICLOVIR; GEMCITABINE; IMMUNOSUPPRESSIVE AGENT; LISDEXAMFETAMINE; METRONIDAZOLE N,N DIMETHYLGLYCINATE; MIDODRINE; N CYSTEAMINE CARBAMAZEPINE; N GLYCYL CARBAMAZEPINE; OPIATE ANTAGONIST; PRODRUG; QC 12; QUERCETIN; RAPAMYCIN 28 N,N DIMETHYLGLYCINATE; TACHYKININ RECEPTOR ANTAGONIST; TALAGLUMETAD; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR;

ATTENTION DEFICIT DISORDER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG HAIR LEVEL; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME STABILITY; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; SUSTAINED DRUG RELEASE;

CHALLENGES; DRUG DELIVERY; FORMULATION; HYDROLYSIS; PERMEABILITY; SOLUBILITY; STABILITY; TARGETING; TRANSPORTERS;

AMINO ACIDS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PRODRUGS;

EID: 84885382399     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.10.001     Document Type: Review

References (108)

1. Stella V., Borchardt R., Hageman M., Oliyai R., Maag H., Tilley J. Prodrugs: Challenges and Rewards 2007, Springer, New York.
2. Rautio J., K.H., Heimbach T., Oliyai R., Oh D., Järvinen T., Savolainen J. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 2008, 7:255-270.
3. Stella V.J. Prodrugs: some thoughts and current issues. J. Pharm. Sci. 2010, 99:4755-4765.
4. Huttunen K.M., Raunio H., Rautio J. Prodrugs-from serendipity to rational design. Pharmacol. Rev. 2011, 63:750-771.
5. Balimane P.V., Tamai I., Guo A., Nakanishi T., Kitada H., Leibach F.H., Tsuji A., Sinko P.J. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 1998, 250:246-251.
6. Sugawara M., Huang W., Fei Y.J., Leibach F.H., Ganapathy V., Ganapathy M.E. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 2000, 89:781-789.
7. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr. Dis. Treat. 2010, 6:317-327.
8. Vig B.S., Rautio J. Amino acid prodrugs for oral delivery: challenges and opportunities. Ther. Deliv. 2011, 2:959-962.
9. Vig B.S., Lorenzi P.J., Mittal S., Landowski C.P., Shin H.C., Mosberg H.I., Hilfinger J.M., Amidon G.L. Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm. Res. 2003, 20:1381-1388.
10. Ma J. Unnatural amino acids in drug discovery. Chim. Oggi June 2003, 65-68.
11. Cao F., Jia J., Yin Z., Gao Y., Sha L., Lai Y., Ping Q., Zhang Y. Ethylene glycol-linked amino acid diester prodrugs of oleanolic acid for pept1-mediated transport: synthesis, intestinal permeability and pharmacokinetics. Mol. Pharm. 2012, 9(8):2127-2135.
12. Gupta D., Gupta S.V., Lee K.D., Amidon G.L. Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers. Mol. Pharm. 2009, 6:1604-1611.
13. Chan O.H., Schmid H.L., Stilgenbauer L.A., Howson W., Horwell D.C., Stewart B.H. Evaluation of a targeted prodrug strategy of enhance oral absorption of poorly water-soluble compounds. Pharm. Res. 1998, 15:1012-1018.
14. Marathe P.H., Kamath A.V., Zhang Y., D'Arienzo C., Bhide R., Fargnoli J. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother. Pharmacol. 2009, 65:55-66.
15. Gingrich D.E., Reddy D.R., Iqbal M.A., Singh J., Aimone L.D., Angeles T.S., Albom M., Yang S., Ator M.A., Meyer S.L., Robinson C., Ruggeri B.A., Dionne C.A., Vaught J.L., Mallamo J.P., Hudkins R.L. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 2003, 46:5375-5388.
16. Mulholland P.J., Ferry D.R., Anderson D., Hussain S.A., Young A.M., Cook J.E., Hodgkin E., Seymour L.W., Kerr D.J. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Ann. Oncol. 2001, 12:245-248.
17. Bundgaard H., Larsen C., Thorbek P. Prodrugs as drug delivery systems XXVI. Preparation and enzymatic hydrolysis of various water-soluble amino acid esters of metronidazole. Int. J. Pharm. 1984, 18:67-77.
18. Trivellato E., Malesani L., Concilio C. Some new esters of chloramphenicol. IV. Pharmacological research on chloramphenicol glycinate. Farmaco Ed. Sci., Pavia 1958, 13:399-405.
19. Bradshaw T.D., Bibby M.C., Double J.A., Fichtner I., Cooper P.A., Alley M.C., Donohue S., Stinson S.F., Tomaszewjski J.E., Sausville E.A., Stevens M.F. Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol. Cancer Ther. 2002, 1:239-246.
20. Mittal S., Song X., Vig B.S., Amidon G.L. Proline prodrug of melphalan targeted to prolidase, a prodrug activating enzyme overexpressed in melanoma. Pharm. Res. 2007, 24:1290-1298.
21. Pochopin N.L., Charman W.N., Stella V.J. Amino acid derivatives of dapsone as water-soluble prodrugs. Int. J. Pharm. 1995, 121:157-167.
22. Rasheed A., Kumar C.K., Mishra A. Synthesis, hydrolysis studies and phamacodynamic profiles of amide prodrugs of dexibuprofen with amino acids. J. Enzyme Inhib. Med. Chem. 2011, 26:688-695.
23. Kotthaus J., Hungeling H., Reeh C., Kotthaus J., Schade D., Wein S., Wolffram S., Clement B. Synthesis and biological evaluation of l-valine-amidoximeesters as double prodrugs of amidines. Bioorg. Med. Chem. 2011, 19:1907-1914.
24. Hemenway J.N., Jarho P., Henri J.T., Nair S.K., VanderVelde D., Georg G.I., Stella V.J. Preparation and physicochemical characterization of a novel water-soluble prodrug of carbamazepine. J. Pharm. Sci. 2010, 99:1810-1825.
25. Amend J.P., Helgeson H.C. Solubilities of the common l-a-amino acids as a function of temperature and solution pH. Pure Appl. Chem. 1997, 69:935-942.
26. Rautio J., Nevalainen T., Taipale H., Vepsalainen J., Gynther J., Pedersen T., Jarvinen T. Synthesis and in vitro evaluation of aminoacyloxyalkyl esters of 2-(6-methoxy-2-naphthyl)propionic acid as novel naproxen prodrugs for dermal drug delivery. Pharm. Res. 1999, 16:1172-1178.
27. Nam N.H., Kim Y., You Y.J., Hong D.H., Kim H.M., Ahn B.Z. Water soluble prodrugs of the antitumor agent 3-[(3-amino-4-methoxy)phenyl]-2-(3,4,5-trimethoxyphenyl)cyclopent-2-ene-1- one. Bioorg. Med. Chem. 2003, 11:1021-1029.
28. Testa B., Mayer J.M. Hydrolysis in Drug and Prodrug Metabolism 2003, Wiley-VCH, Weinheim.
29. Fort J.J., Mitra A.K. Solubility and stability characteristics of a series of methrotrexate dialkyl esters. Int. J. Pharm. 1990, 59:271-279.
30. Bundgaard H., Larsen C., Arnold E. Prodrugs as drug delivery systems XXVII. Chemical stability and bioavailability of a water-soluble prodrug of metronidazole for parenteral administration. Int. J. Pharm. 1984, 18:79-87.
31. Colla L., De Clercq E., Busson R., Vanderhaeghe H. Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. J. Med. Chem. 1983, 26:602-604.
32. Wu Z., Patel A., Dave R., Yuan X. Development of acetaminophen proline prodrug. Bioorg. Med. Chem. Lett. 2010, 20:3851-3854.
33. Jensen E., Bundgaard H., Falch E. Design of a water-soluble, solution-stable and biolabile prodrug of metronidazole for parenteral administration: N-substituted aminomethylbenzoate esters. Int. J. Pharm. 1990, 58:143-153.
34. Anderson B.D., Conradi R.A., Knuth K.E. Strategies in the design of solution-stable, water-soluble prodrugs I: a physical-organic approach to pro-moiety selection for 21-esters of corticosteroids. J. Pharm. Sci. 1985, 74:365-374.
35. Bundgaard H., Falch E., Jensen E. A novel solution-stable, water-soluble prodrug type for drugs containing a hydroxyl or an NH-acidic group. J. Med. Chem. 1989, 32:2503-2507.
36. Jensen E., Bundgaard H. N-substituted (aminomethyl)benzoate 21-esters of corticosteroids as water-soluble, solution-stable and biolabile prodrugs. Acta Pharm. Nord. 1992, 4:35-42.
37. Landowski C.P., Vig B.S., Song X., Amidon G.L. Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol. Cancer Ther. 2005, 4:659-667.
38. Vig B.S., Lorenzi P.J., Mittal S., Landowski C.P., Shin H.C., Mosberg H.I., Hilfinger J.M., Amidon G.L. Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm. Res. 2003, 20:1381-1388.
39. Liang Y., Sharon A., Grier J.P., Rapp K.L., Schinazi R.F., Chu C.K. 5'-O-Aliphatic and amino acid ester prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine (DOT): synthesis, anti-HIV activity, cytotoxicity and stability studies. Bioorg. Med. Chem. 2009, 17:1404-1409.
40. Granero G.E., Amidon G.L. Stability of valacyclovir: implications for its oral bioavailability. Int. J. Pharm. 2006, 317:14-18.
41. Song X., Lorenzi P.L., Landowski C.P., Vig B.S., Hilfinger J.M., Amidon G.L. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol. Pharm. 2005, 2:157-167.
42. Kim I., Chu X.Y., Kim S., Provoda C.J., Lee K.D., Amidon G.L. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J. Biol. Chem. 2003, 278:25348-25356.
43. Kim I., Song X., Vig B.S., Mittal S., Shin H.C., Lorenzi P.J., Amidon G.L. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol. Pharm. 2004, 1:117-127.
44. Lai L., Xu Z., Zhou J., Lee K.D., Amidon G.L. Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J. Biol. Chem. 2008, 283:9318-9327.
45. Burnette T.C., Harrington J.A., Reardon J.E., Merrill B.M., de Miranda P. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the l-valyl ester prodrug of acyclovir. J. Biol. Chem. 1995, 270:15827-15831.
46. Stella V.J., Nti-Addae K.W. Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev. 2007, 59:677-694.
47. Fleisher D., Bong R., Stewart B.H. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Adv. Drug Deliv. Rev. 1996, 19:115-130.
48. Diaz-Padilla I., Siu L.L. Brivanib alaninate for cancer. Expert Opin. Investig. Drugs 2011, 20:577-586.
49. Huynh H., Fargnoli J. Brivanib alaninate: VEGFR/FGFR inhibitor oncolytic. Drug Future 2009, 34:881-895.
50. Gong J., Gan J., Caceres-Cortes J., Christopher L.J., Arora V., Masson E., Williams D., Pursley J., Allentoff A., Lago M., Tran S.B., Iyer R.A. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans. Drug Metab. Dispos. 2011, 39:891-903.
51. Jones-Bolin S., Zhao H., Hunter K., Klein-Szanto A., Ruggeri B. The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol. Cancer Ther. 2006, 5:1744-1753.
52. Ruggeri B., Singh J., Gingrich D., Angeles T., Albom M., Yang S., Chang H., Robinson C., Hunter K., Dobrzanski P., Jones-Bolin S., Pritchard S., Aimone L., Klein-Szanto A., Herbert J.M., Bono F., Schaeffer P., Casellas P., Bourie B., Pili R., Isaacs J., Ator M., Hudkins R., Vaught J., Mallamo J., Dionne C. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. 2003, 63:5978-5991.
53. Kim M.K., Oh Y.M., Park K.-s., Chong Y. A novel prodrug of quercetin, 3-N,N-dimethyl carbamoyl quercetin (DCQ), with improved stability against hydrolysis in cell culture medium. Bull. Korean Chem. Soc. 2009, 30:2114-2116.
54. Ferry D.R., Smith A., Malkhandi J., Fyfe D.W., deTakats P.G., Anderson D., Baker J., Kerr D.J. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res. 1996, 2:659-668.
55. Vissiennon C., Nieber K., Kelber O., Butterweck V. Route of administration determines the anxiolytic activity of the flavonols kaempferol, quercetin and myricetin - are they prodrugs? 2012, J. Nutr, Biochem.
56. Chan O.H., Stewart B.H. Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Discov. Today 1996, 1:461-473.
57. Li A.P. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov. Today 2001, 6:357-366.
58. Brandsch M., Knutter I., Bosse-Doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. J. Pharm. Pharmacol. 2008, 60:543-585.
59. Yang C., Tirucherai G.S., Mitra A.K. Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin. Biol. Ther. 2001, 1:159-175.
60. Broer S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol. Rev. 2008, 88:249-286.
61. Soul-Lawton J., Seaber E., On N., Wootton R., Rolan P., Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the l-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother. 1995, 39:2759-2764.
62. de Miranda P., Blum M.R. Pharmacokinetics of acyclovir after intravenous and oral administration. J. Antimicrob. Chemother. 1983, 12(Suppl. B):29-37.
63. Vergin H., Kikuta C., Mascher H., Metz R. Pharmacokinetics and bioavailability of different formulations of aciclovir. Arzneimittelforschung 1995, 45:508-515.
64. Hatanaka T., Haramura M., Fei Y.J., Miyauchi S., Bridges C.C., Ganapathy P.S., Smith S.B., Ganapathy V., Ganapathy M.E. Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB(0,+) and expression of the transporter in tissues amenable for drug delivery. J. Pharmacol. Exp. Ther. 2004, 308:1138-1147.
65. Elion G.B., Furman P.A., Fyfe J.A., de Miranda P., Beauchamp L., Schaeffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U. S. A. 1977, 74:5716-5720.
66. Miller W.H., Miller R.L. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J. Biol. Chem. 1980, 255:7204-7207.
67. Umapathy N.S., Ganapathy V., Ganapathy M.E. Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm. Res. 2004, 21:1303-1310.
68. Anderson R.D., Griffy K.G., Jung D., Dorr A., Hulse J.D., Smith R.B. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin. Ther. 1995, 17:425-432.
69. Jung D., Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J. Clin. Pharmacol. 1999, 39:800-804.
70. Warren M.S., Rautio J. Prodrugs designed to target transporters for oral drug delivery. Prodrugs and Targeted Delivery - Towards Better ADME Properties 2011, 133-151. Wiley-VCH Verlag & Co. KGaA, Weinheim. J. Rautio (Ed.).
71. Tsuda M., Terada T., Irie M., Katsura T., Niida A., Tomita K., Fujii N., Inui K. Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J. Pharmacol. Exp. Ther. 2006, 318:455-460.
72. Cruz D.N. Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension. Expert Opin. Pharmacother. 2000, 1:835-840.
73. Dunayevich E., Erickson J., Levine L., Landbloom R., Schoepp D.D., Tollefson G.D. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008, 33:1603-1610.
74. Rorick-Kehn L.M., Perkins E.J., Knitowski K.M., Hart J.C., Johnson B.G., Schoepp D.D., McKinzie D.L. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J. Pharmacol. Exp. Ther. 2006, 316:905-913.
75. Varma M.V., Eriksson A.H., Sawada G., Pak Y.A., Perkins E.J., Zimmerman C.L. Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarbox ylate (LY544344). Drug Metab. Dispos. 2009, 37:211-220.
76. Cundy K.C., Branch R., Chernov-Rogan T., Dias T., Estrada T., Hold K., Koller K., Liu X., Mann A., Panuwat M., Raillard S.P., Upadhyay S., Wu Q.Q., Xiang J.N., Yan H., Zerangue N., Zhou C.X., Barrett R.W., Gallop M.A. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J. Pharmacol. Exp. Ther. 2004, 311:315-323.
77. Lal R., Sukbuntherng J., Tai E.H., Upadhyay S., Yao F., Warren M.S., Luo W., Bu L., Nguyen S., Zamora J., Peng G., Dias T., Bao Y., Ludwikow M., Phan T., Scheuerman R.A., Yan H., Gao M., Wu Q.Q., Annamalai T., Raillard S.P., Koller K., Gallop M.A., Cundy K.C. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J. Pharmacol. Exp. Ther. 2009, 330:911-921.
78. Goodman D.W. Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. Pharm. Ther. 2010, 35:273-287.
79. Elia J., Easley C., Kirkpatrick P. Lisdexamfetamine dimesylate. Nat. Rev. Drug Discov. 2007, 6:343-344.
80. Stella V.J., Kennedy P.E. Water-Soluble Rapamycin Prodrugs 1987.
81. Supko J.G., Malspeis L. Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. Cancer Chemother. Pharmacol. 1994, 33:325-330.
82. Pochopin N.L., Charman W.N., Stella V.J. Pharmacokinetics of dapsone and amino acid prodrugs of dapsone. Drug Metab. Dispos. 1994, 22:770-775.
83. Hemenway J.N., Stella V.J. In vitro and in vivo evaluation of a novel water-soluble N-glycyl prodrug (N-GLY-CBZ) of carbamazepine. J. Pharm. Sci. 2010, 99:4565-4575.
84. Hemenway J.N., Nti-Addae K., Guarino V.R., Stella V.J. Preparation, characterization and in vivo conversion of new water-soluble sulfenamide prodrugs of carbamazepine. Bioorg. Med. Chem. Lett. 2007, 17:6629-6632.
85. Ehrlich P. Principles of experimental chemotherapy. Angew. Chem. 1910, 2-8.
86. Katragadda S., Gunda S., Hariharan S., Mitra A.K. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections. Int. J. Pharm. 2008, 359:15-24.
87. Patel K., Trivedi S., Luo S., Zhu X., Pal D., Kern E.R., Mitra A.K. Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir. Int. J. Pharm. 2005, 305:75-89.
88. Majumdar S., Nashed Y.E., Patel K., Jain R., Itahashi M., Neumann D.M., Hill J.M., Mitra A.K. Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J. Ocul. Pharmacol. Ther. 2005, 21:463-474.
89. Kwak E.Y., Shim W.S., Chang J.E., Chong S., Kim D.D., Chung S.J., Shim C.K. Enhanced intracellular accumulation of a non-nucleoside anti-cancer agent via increased uptake of its valine ester prodrug through amino acid transporters. Xenobiotica 2012.
90. Gynther M., Jalkanen A., Lehtonen M., Forsberg M., Laine K., Ropponen J., Leppanen J., Knuuti J., Rautio J. Brain uptake of ketoprofen-lysine prodrug in rats. Int. J. Pharm. 2010, 399:121-128.
91. Gynther M., Laine K., Ropponen J., Leppanen J., Mannila A., Nevalainen T., Savolainen J., Jarvinen T., Rautio J. Large neutral amino acid transporter enables brain drug delivery via prodrugs. J. Med. Chem. 2008, 51:932-936.
92. Peura L., Malmioja K., Laine K., Leppanen J., Gynther M., Isotalo A., Rautio J. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. Mol. Pharm. 2011, 8:1857-1866.
93. Chrzanowski K., Bielawska A., Palka J. Proline analogue of melphalan as a prodrug susceptible to the action of prolidase in breast cancer MDA-MB 231 cells. Farmaco 2003, 58:1113-1119.
94. Wu Z., Shah A., Patel N., Yuan X. Development of methotrexate proline prodrug to overcome resistance by MDA-MB-231 cells. Bioorg. Med. Chem. Lett. 2010, 20:5108-5112.
95. Tsume Y., Amidon G.L. The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme. Molecules 2012, 17:3672-3689.
96. Lorenzi P.L., Landowski C.P., Brancale A., Song X., Townsend L.B., Drach J.C., Amidon G.L. N-methylpurine DNA glycosylase and 8-oxoguanine dna glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(beta-d-ribofuranosyl)benzimidazole. Drug Metab. Dispos. 2006, 34:1070-1077.
97. Lorenzi P.L., Landowski C.P., Song X., Borysko K.Z., Breitenbach J.M., Kim J.S., Hilfinger J.M., Townsend L.B., Drach J.C., Amidon G.L. Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-d-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo. J. Pharmacol. Exp. Ther. 2005, 314:883-890.
98. Alsenz J., Kansy M. High throughput solubility measurement in drug discovery and development. Adv. Drug Deliv. Rev. 2007, 59:546-567.
99. Balimane P.V., Chong S., Morrison R.A. Current methodologies used for evaluation of intestinal permeability and absorption. J. Pharmacol. Toxicol. Methods 2000, 44:301-312.
100. Liederer B.M., Borchardt R.T. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci. 2006, 95:1177-1195.
101. Browning M.R., Drexler D.M., Olah T.V., Morgan D.G. Simultaneous bioanalysis of a phosphate prodrug and its parent compound using a multiplexed LC-MS method. Bioanalysis 2010, 2:745-753.
102. He B.L., Shi Y., Kleintop B., Raglione T. Direct and indirect separations of five isomers of Brivanib Alaninate using chiral high-performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 875:122-135.
103. Badawy S.I., Williams R.C., Gilbert D.L. Chemical stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist in solid dosage forms. J. Pharm. Sci. 1999, 88:428-433.
104. Narang A.S., Yamniuk A.P., Zhang L., Comezoglu S.N., Bindra D.S., Varia S., Doyle M.L., Badawy S. Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs. J. Pharm. Pharmacol. 2012, 64:553-565.
105. Fyfe H., Shi Y., Zhang L. Hydrolysis and Crosslinking Investigation on the Dissolution of a Pro-drug Capsule Formulation. AAPS Annual Meeting 2007.
106. Wu K.M., Farrelly J.G. Regulatory perspectives of type II prodrug development and time-dependent toxicity management: nonclinical Pharm/Tox analysis and the role of comparative toxicology. Toxicology 2007, 236:1-6.
107. Bier D.M., Young V.R. A kinetic approach to assessment of amino acid and protein replacement needs of individual sick patients. JPEN: J. Parenter. Enteral. Nutr. 1987, 11:95S-97S.
108. Gulati D.K., Chambers C.L., Rosenthal G.L., Sabharwal P.S. Comparative toxicity of some naturally occurring and synthetic non-protein aminoacids. Environ. Exp. Bot. 1981, 21:225-230.